Background: plays an important role in the innate and adaptive immune responses, it can also cause severe allergic inflammatory reactions. Thus it is a molecule currently being targeted for therapy. The natural intrinsic inhibitor of IL-18 receptor activation, IL-18 binding protein (IL-18BP), shows a great potential for the treatment of allergy.
INTRODUCTION
Interleukin-18 (IL-18) is a cytokine originally found to induce the production of interferon-gamma (IFN-γ) in T lymphocytes, and plays an important role in innate and adaptive immune systems. 1, 2 To initiate the IL-18 pathway, the IL-18 receptor needs to be activated, which requires IL-18 receptor alpha (IL-18Rα, formerly known as IL-1Rrp) and IL-18 receptor beta (IL-18Rβ, formerly known as IL-1RAcPL) to heterodimerize. 2 The structure of human IL-18 has been determined and it has shown that hIL-18 contains the β-trefoil fold that is similar to those found in interleukin-1 (IL-1) family members, making a new structural family in the interleukins. 3, 4 Also, using mutant recombinant human IL-18 (rhIL-18) proteins in receptor-binding and cellular response assays, three important binding sites have been identified. 3 Two of these sites are important for binding to IL-18Rα, and the third is in-volved in cellular responses but not in IL-18Rα binding. 3 By comparing the structure and the receptor binding sites of IL-18 with those of the IL-1 family members, a two-step ternary complex formation that involves IL-18, IL-18Rα, and IL-18Rβ has been revealed. 4 The formation of the ternary complex can then trigger a signal cascade that activates IL-1 receptor activating kinase (IRAK), tumor necrosis factor (TNF)-receptor associated factor 6 (TRAF6) and nuclear factor-kappa B (NF-κB). 5, 6 In medicine, the aberrant expression of IL-18 has been suggested to be responsible for several inflammatory conditions, such as allergies, autoimmune diseases, and neurological disorders. 2, 7 Serum concentrations of IL-18 and IgE have been correlated with disease severity in atopic dermatitis (AD) patients. [7] [8] [9] In these patients, the serum concentration of IL-18 is significantly higher than that found in healthy individuals. 9 Furthermore, in response to lipopolysaccharide (LPS), leukocytes prepared from the peripheral blood of AD patients produced more IL-18 than the cells of healthy individuals. 7, 8 In patients with bronchial asthma, the level of serum IL-18 is also elevated, and seems to correlate with disease severity. 7, [10] [11] [12] [13] [14] As well, polymorphic genes for IL-18 and IL-18Rα have been found in association with allergy. [15] [16] [17] Collectively, these studies strongly suggest that IL-18 is responsible for causing and! or maintaining inflammatory conditions. Thus, IL-18 may be an ideal therapeutic target for the treatment of allergy. 7 In clinical settings, humanized antibodies are widely used as therapeutic agents for the treatment of many diseases, including allergy. 18 Although anti-IL-18 antibody has been proven to be effective for preventing liver damage in mice, to date, there are no specific inhibitors against IL-18 to treat patients. 1, 7, 18 To this end, Hamasaki et al. recently reported a human anti-hIL-18 antibody (h18 108) that is capable of inhibiting IFN-γ production in a cell line. 19 For therapeutic purposes, IL-18 binding protein (IL-18BP), a natural intrinsic inhibitor of hIL-18, may be an ideal candidate for use as a therapeutic agent. 20 One reason is that it is a natural inhibitor of IL-18, and its functional homologs have also been found in poxviruses, which utilize proteins to evade the immune system. [21] [22] [23] [24] [25] [26] Also, the severity of autoimmune diseases appears to be influenced by the relative levels of IL-18 and IL-18BP. 27 Furthermore, IL-18BP has been shown to prevent disease development in various mouse models, which strongly supports IL-18BP's potential as a therapeutic agent. [28] [29] [30] In this study, we performed high expression and purification of recombinant human IL-18BP (rhIL-18BP) using the baculovirus system to develop a therapeutic molecule for the treatment of IL-18-related diseases. A structural analysis of rhIL-18BP was performed to investigate the structural basis of its inhibitory mechanism.
METHODS

CONSTRUCTION OF EXPRESSION VECTOR FOR hIL-18BP
The IL-18BP isoform-a was selected from six isoforms of IL-18BP, because isoform-a most strongly inhibits IL-18 activity on human peripheral blood mononuclear cells (PBMCs) or human cell lines and has been widely used as the representative of the isoforms. 31, 32 Total mRNA was extracted from the blood of a healthy volunteer, and single-stranded cDNAs were synthesized at 72 for 60 minutes using reverse transcriptase and oligo-dT primers. Only the coding region of the mature hIL-18BP isoform a (NM173042, residues 27 193 aa,) was amplified by PCR. The amplified fragment was cloned into Tvector (Invitrogen, USA), because the amino acid residues 1 to 26 of the hIL-18BP are recognized as a signal peptide in mammalian cells (Fig. 1A) . One of the primers used in the PCR contained an EcoRI site and a signal peptide sequence for Sf9 insect cells, and by design, these were placed immediately upstream of the first codon of the mature hIL-18BP. The second primer contained the His-6 tag sequence, a stop codon, and a NotI site. The purified PCR product was subcloned into the pFastBac1 vector (Invitrogen, USA). The DNA sequence of the clone was confirmed by bi-directional sequencing. The construct was called pFastBac1-hIL-18BP-His6 (Fig. 1B) .
PRODUCTION OF RECOMBINANT BACULOVI-RUS
Generation of recombinant baculovirus expressing hIL-18BP in Sf9 cells was carried out with a Bac-toBac baculovirus expression kit (Invitrogen, USA). In accord with the manufacturer's protocol, pFastBac1-hIL-18BP-His6 was introduced into E.coli DH10Bac (Invitrogen, USA) for the transposition of IL-18BP into baculovirus genomic DNA (bacmid). Colonies containing the recombinant bacmid were isolated using a miniprep plasmid isolation kit (Promega, USA). The recombinant bacmid DNA was then used to transfect Sf9 cells, which were plated at a density of 1 × 10 6 cells per 35-mm well and then transfected with the bacmid DNA using Cellfectin reagent (Invitrogen, USA). The recombinant virus was harvested 72 hours post-transfection. Plaque assays were performed with the supernatants to determine the titer of recovered virion particles. Plaque assay and propagation of viruses were carried out according to the manual provided with the kit.
INSECT CELL CULTURE
Sf9 insect cells were cultured and routinely subcultured at 27 . They were maintained either as a monolayer or as a suspension culture in Sf-900 II SFM (Invitrogen, USA) without antibiotics. Insect . L a n e 1 : me d i u m, l a n e 2 : DE A E , l a n e 3 : Ni NT A , l a n e 4 : Ge l f i l t r a t i o n . D, De g l y c o s y l a t i o n b y t r i f l u o r o me t ha n e s u l f o n i c a c i d . L a n e 1 : b e f o r e d e g l y c o s y l a t i o n , l a n e 2 : a f t e r d e g l y c o s y l a t i o n . 
cells in a monolayer culture were plated at a density of 1.0 × 10 6 cells! well in six-well plates. These cells were used to transfect recombinant bacmid DNA or for the determination of the optimal multiplicity of infection (MOI). The cells in the suspension culture were grown in a 25 ml volume of Sf-900 II SFM using 125 ml disposable Erlenmeyer flasks (Nalgene, USA). The flasks were maintained in a Bioshaker BR40LF (TAITEC, Japan) and were subjected to rotary shaking at a speed of 95 rpm (amplitude 35 mm). Stock Sf9 cells that were grown in suspension were seeded at 0.5 × 10 6 cells! ml and culture passage was performed every 3 days during the log phase (4 6 × 10 6 cells! ml).
PURIFICATION OF hIL-18BP FROM BACULO-VIRUS-INFECTED SF9 CELL CULTURE MEDIUM
For the purification of rhIL-18BP, Sf9 cells were subcultured in 1 L Fernbach flasks. Each flask received 400 ml of the cell culture at a concentration of 0.5 × 10 6 cells! ml. Shaking speed was set to 71 rpm (Amplitude 50 mm). When the subcultured cells reached a concentration of 2.0 × 10 6 cells! ml, Sf9 cells were infected with the recombinant baculovirus at an MOI of 0.1 plaque-forming units (pfu) per ml and were incubated for up to 72 hours. Secreted rhIL-18BP was processed by centrifugation and filtration. Then, the medium was applied to a DEAE-Sepharose (GE health care, Sweden) open column (Bio-Rad, USA) equilibrated with buffer A (50 mM sodium-phosphate, pH 6.0 containing 50 mM NaCl). The flow through was concentrated 10-fold using a tangential flow filtration system; Masterflex L! S (Barnant Company, USA) and viva flow 50 (Vivasciece AG, Germany). This was then dialyzed against buffer B (50 mM Sodium Phosphate, 0.5 M NaCl, 10 mM Imidazol, pH 7.4) and insoluble material removed by centrifugation at 2 × 10 4 g; himac CR 20B2 (Hitachi, Japan). Dialyzed sample was loaded onto a Ni-agarose (GE Healthcare, Sweden) column equilibrated with buffer B. The column was then washed with buffer B and bound proteins were eluted by an elution buffer B with varying imidazol concentrations (50, 100, 200, 300 and 500 mM). The eluted fraction of rhIL-18BP was concentrated and further purified using a superdex75 16! 60 (GE Healthcare, Sweden) size exclusion column equilibrated with 50 mM potassium phosphate buffer pH 7.0, containing 150 mM KCl and 0.1 mM EDTA. The purity of the preparation was assessed by SDS-PAGE.
DEGLYCOSYLATION OF rhIL-18BP BY TRIFLU-OROMETHANE SULFONIC ACID
Deglycosylation was performed in a draft chamber (DF-19RST, DALTON, Japan). Freeze dried IL-18BP (30 μg) in glass vial and trifluoromethane sulfonic acid (TFMS) (Sigma Aldrich, Japan) was chilled on ice prior to mixing. Fifty micro liters of TFMS was added in a glass vial and gently mixed. The vial was then incubated for 50 hours on ice and neutralized with a solution of 500 μl of 1M-Tris. Neutralized rhIL-18BP was concentrated with a MicroconYM-10 (Millipore, USA) and dialyzed against 20 mM sodium phosphate buffer of pH 7.0 containing 150 mM NaCl before SDS-PAGE.
N-TERMINAL SEQUENCING BY EDMAN DEGRA-DATION
Purified proteins were electro-blotted onto a polyvinylidene difluoride membrane (Amersham Biosciences, UK) after SDS-PAGE for 1 hour at 200 mA in solution that contained 25 mM Tris, 192 mM glycine, and 10% methanol. The membrane was briefly stained with CBB R250 (Wako, Japan) and de-stained extensively in 45% and 90% methanol containing 7% acetic acid. The amino acid sequence analysis of the recombinant protein was carried out by an Edman degradation technique using a pulse liquid automatic sequencer (Model 491HT, Applied Biosystems, USA).
FUNCTIONAL ANALYSIS OF rhIL-18BP
Biological activity of rhIL-18BP was assayed by measuring its ability to inhibit the production of IFN-γ. This was performed as previously described with minor modifications. 17 Briefly, PBMCs were isolated from three volunteers and suspended at 1 × 10 6 ! ml in the culture medium. PBMCs were cultured in the presence or absence of 1 ng! ml of the LPS with or without rhIL-18BP (400 ng! ml) for 24 hours at 37 in a humidified atmosphere containing 5% CO2. The cell culture supernatants were collected in test tubes, and the samples were spun to get rid of cells and then stored at −80 until assay. The concentration of IFN-γ was measured by enzyme-linked immunosorbent assay (ELISA), as previously described. 32 
MEASUREMENT OF rhIL-18BP-MEDIATED INHI-BITION OF IFN-γ PRODUCTION IN KG-1 CELLS
In hIL-18 inhibition assay, the level of inhibition is determined by the amount of IFN-γ produced by the target cells. A detailed description has been reported. 32 Briefly, human myelomonocytic KG-1 cells (ATCC CCL246) were grown in RPMI1640 (Invitrogen, USA) supplemented with 10% heat-inactivated fetal calf serum (Sigma Aldrich, USA), L-glutamine (2 mmol! L) (Wako, Japan), penicillin (100 U! ml) (Meiji, Japan), and streptomycin (100 μg! ml) (Meiji, Japan). The rhIL-18 and rhIL-18BP prepared in our laboratory were mixed in the RPMI1640 medium noted above. The concentration of rhIL-18 was 4 ng! ml and rhIL-18BP was from 0 to 250 ng! ml. The mixed samples were incubated at 37 for 1 hour. Then, 100 μl of the mixture was added to the wells of a 96-well plate (Nunc, Denmark), which contained 100 μl of KG-1 cells (3 × 10 6 cells! ml) (The final concentration of rhIL-18 was 2 ng! ml and rhIL-18BP was from 0 to 125 ng! ml). The plate was further incubated at 37 for 24 hours in 5% CO2. The culture supernatants were collected, and the amount of IFN-γ produced by KG-1 cells was determined by ELISA. 32 IC50, the concentration of antagonists required to inhibit 50% of IFN-γ production by KG-1 cells stimulated with hIL-18, was then calculated.
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MEASUREMENT OF rhIL-18BP'S BINDING AC-TIVITY BY SURFACE PLASMON RESONANCE EXPERIMENT
In vitro affinity of the hIL-18 for rhIL-18BP was measured at 25 by surface plasmon resonance (SPR) using a BIAcore3000 (BIAcore, Sweden). A specific binding surface was prepared by coupling the antipenta-His antibody (QIAGEN K.K, Japan) to a CM5 sensor chip by the standard amine coupling method, as recommended by BIAcore. Then, 6-his tagged rhIL-18BP was injected over the sensor chip and immobilized. The coupling density was limited to 120 resonance units (RU) . Samples of hIL-18 were diluted to varying concentrations ranging from 2 to 32 nM in HBS-EP buffer (10 mM HEPES, pH 7.4, 150 mM NaCl, 3.0 mM EDTA, 0.005% (v! v) surfactant P-20). For dissociation constant analysis, diluted hIL-18 samples were injected over the sensor chip at a flow rate of 20 μl! min. The sensor surface was regenerated by two 60-second pulses of 0.2 M glycine-HCl, pH 2.2. The sensorgrams obtained from various concentrations of rhIL-18 were fitted with BIAEVALU-ATION software (BIAcore, Sweden) in a 1-to-1 binding model.
ANALYTICAL GEL FILTRATION OF rhIL-18BP
The molecular mass of purified rhIL-18BP and the complex of rhIL-18 and rhIL-18BP were determined by size exclusion chromatography. A superdex200 10! 30 GL column (GE Healthcare, Sweden) attached to a FPLC system (GE Healthcare, Sweden) was utilized and the study conducted at 4 . The column was equilibrated with 50 mM potassium phosphate buffer of pH 7.0, containing 150 mM KCl and 0.1 mM EDTA. The column was calibrated with the following gel filtration standards (Bio-Rad Laboratories, USA): thyroglobulin (670 kDa), bovine γ-globulin (158 kDa), chicken ovalbumin (44 kDa), equine myoglobin (17 kDa), and vitamin B12 (1.35 kDa) at a flow rate of 0.25 ml! min. Samples with only hIL-18BP, only rhIL-18 or a mixture of rhIL-18BP and rhIL-18 at a 1 : 2 ratio were used for the analysis. Protein elution was monitored and detected by UV absorption at 280 nm. We plotted the logarithm of the molecular weight versus the elution volume, and calculated the correlation line. The elution volume of rhIL-18BP and the complex of rhIL-18! rhIL-18BP were plotted and the deduced molecular weight determined. 
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HOMOLOGY MODELING OF THE STRUCTURES
The sequence alignment of IL-18BP from different species was performed using ClustalW (http:! ! www2. ebi.ac.uk! clustalw! ) with a BLOSUM matrix. Homology modeling was performed using MOE software (CCG, Inc., Canada) with a combination of segmentmatching and modeling of indels. 33, 34 The templates used for the modeling were as follows: the NMR structure of hIL-18 (PDB: 1J0S) and the crystal structure of the domain 3 of hIL-1Rα (PDB: 1ITB) for the hIL-18: hIL-18BP complex; the NMR structure of hIL-18 (PDB: 1J0S) and the crystal structure of the hIL-10! anti-IL-10 Fab complex (PDB: 1LK3) for the hIL-18! human anti-hIL-18 Fab interaction. The modeled structures were refined by further energy minimization.
RESULTS
CHARACTERIZATION OF THE PURIFIED rhIL-18BP
High expressions of rhIL-18BP were obtained using the baculovirus expression system. We were able to obtain a yield of 2.5 mg! L of rhIL-18BP after Ni-NTA column purification (Fig. 1C) . A further purification by gel filtration showed excellent purity and yielded 1.8 mg! L (Fig. 1C) . To check the purity of the protein, electrophoresis was performed. Although the band appeared smeary, when we deglycosylated it with TFMS, a single sharp band of 18 kDa in size was detected (Fig. 1D) . Edman degradation analysis of rhIL-18BP revealed the expected five N-terminal amino acid residues: (LVRAT). The sequence verified the identity of the expressed protein and indicated that the signal peptide from the vector was correctly cleaved at the N-terminal residue of mature rhIL-18 BP.
FUNCTIONAL ACTIVITY OF THE rhIL-18BP
The biological activity of rhIL-18BP was tested by measuring its ability to inhibit the production of IFN-γ by LPS-stimulated PBMCs from volunteers ( Fig. 2A) . The rhIL-18BP showed distinct inhibitory actions against IFN-γ production by PBMCs in response to LPS. rhIL-18BP only partly inhibited IFN-γ production by PBMCs from volunteer #1, while it almost completely inhibited those from volunteers #2 and #3 ( Fig. 2A) . This diversity might be partly explained by the different amounts of IL-18 released from PBMCs of individual volunteers and! or in part by the different productions of other IFN-γ-related cytokines, such as IL-12 and IL-15. 8, 17, 35, 36 As well, rhIL-18BP inhibited the production of IFN-γ by human KG-1 cells in the presence of IL-18 (IC50 = 0.4 nM, Fig. 2B ).
His-tagged rhIL-18BP was immobilized on a BIAcore sensor chip coated with anti-His-tag antibodies and its binding activity monitored in real time with a BIAcore 3000 sensor. A sensorgram of rhIL-18 showed a rapid increase in signal during the association phase and a slow decline in the dissociation phase (Fig. 2C) , demonstrating a fast on-rate and a slow off-rate. The estimated Kd of 0.46 nM was similar to results previously reported, indicating that the produced rhIL-18BP had proper structural folding. 25, 26, 31 
STRUCTURAL ANALYSIS OF rhIL-18BP
Gel filtration analysis revealed that rhIL-18BP is a monomer in solution (Fig. 3A) and that a complex of rhIL-18 and rhIL-18BP could be made in the same molar ratio (Fig. 3B) . Together with the molecular weight of the complex, it is suggested that the complex could be made by one hIL-18 and one hIL-18BP (Fig. 3B) .
Based on the results of analytical gel filtration, a model structure of the rhIL-18! rhIL-18BP complex was constructed using the NMR structure of hIL-18 and the crystal structure of the domain 3 of IL-1Rα as templates 3 (Fig. 4) . The analysis of the amino acid sequence alignment for IL-18BP revealed that the residues that are involved in the binding of hIL-18 are highly conserved between species 25, 26 (Fig. 1A) . Our model showed that the three key residues (F93, Y97, and F104) that are involved in binding IL-18 make hydrophobic patches that align with the binding interfaces of hIL-18 (Fig. 4C) . The three key residues of hIL-18 for binding (L5, K53, and S55) have been shown to be involved in the interaction with hIL-18BP. 26 
DISCUSSION
Our previous structural analysis of the IL-18! IL-18 receptor interaction showed that there are 3 distinct and important binding sites on the surface of IL-18 (Fig. 5A) . 3 Two of the sites (Sites 1 and 2) are responsible for binding to IL-18Rα while the third site is involved in binding to IL-18Rβ (Fig. 5A B) . Site 2 residue is also important for IL-18BP binding 3 (Fig. 5A  C) . A recent study showed that a single-chain Fv (scFv) of an anti-human IL-18 antibody binds to Site 3 of IL-18 (Fig. 5A D) . 19 scFv (h18 108) showed a moderate binding affinity (Kd = 50 nM), whereas the Fab fragment of h18 108 showed a higher affinity (Kd = 3.7nM), suggesting that the stability of the binding surface structure could improve the affinity. 19 Further, hIL-18BP, which has a smaller molecular mass than scFv, showed a greater than 100-fold higher affinity (Kd = 0.46 nM) 25, 26, 31 than scFV. This suggested that the evolutionally improved structure of IL-18BP provided an optimal biding surface complementarity. Based on this, perhaps one could optimize the binding affinity of h18 108 by modifying the surface structure through in vitro mutagenesis or through a computational design, as it has been demonstrated for the anti-epidermal growth factor receptor drug, Cetuximab. 37 IL-18 activates IL-18 receptor through a two-step binding mechanism as shown 3 in Figure 6 . According to this model, the inhibitory mechanisms of IL-18BP and the Fab fragment of h18 108 antibody are different (Fig. 6) . IL-18BP inhibits the receptor activation by competing for Site 2 on IL-18, which is also a binding site for IL-18Rα. On the other hand, the Fab fragment of h18 108 antibody binds to Site 3 on IL-18 to block IL-18 from binding to IL-18Rβ 3 (Fig. 6) . The IC50 of IL-18BP has been shown to fall in the range of 0.04 0.46 nM, while it is 100 nM for the Fab frag-ment. 19 This huge difference in IC50 may reflect the type of inhibitory mechanism that is employed (Fig.  6) . Interestingly, an intact form of h18 108 antibody, an IgG molecule, has a much higher affinity with a Kd of 0.64 nM and an IC50 of 5 nM. 19 This improvement is most likely the result of its overall stability and the bivalency of the intact antibody molecule. Regardless of the affinity, these different molecules will be useful for determining the precise mechanism by which IL-18 receptor is activated or inhibited. Information gained from such studies will undoubtedly help us design potent therapeutic reagents.
A number of drugs targeting and neutralizing the deleterious effects of cytokines have been developed. Etanercept is a soluble fusion protein that is composed of two tumor necrosis factor alpha (TNF-α) receptors (p75) and a Fc fragment of a human IgG1 molecule; it has been shown to be effective and safe in patients with rheumatoid arthritis. 38 Recently, it was reported that the blockade of TNF-α by etanercept had efficacy in patients with asthma. 39, 40 In addition to the anti-TNF drugs, the role of IL-18 in allergy suggests that drugs that neutralize the effect of IL-18, such as monoclonal antibodies or IL-18BP, may also be useful for the management of allergy. 7 The chemical characteristics of IL-18BP (a single polypeptide, a monomer, and with a low molecular weight of 25 kDa) support its use in clinical settings. Because of these characteristics, it is possible that its dosage could be lower than that of molecules, such as monoclonal antibodies and etanercept (multiple polypeptides, oligomer, high molecular weight of > 300 kDa) that are much bigger and more complex. Establishing a system that enables researchers to highly express the desired protein to study its structural mechanism could open avenues of research to develop new reagents and strategies for the treatment of various diseases, including allergy.
